The data reviewed herein suggest the potential applicability of PD-1 or PD-L1, which provide a rationale for the use of anti-PD-1 or PD-L1 mAbs in the treatment of high-risk metastatic tumors. The gene discussed is CD274; the disease is metastatic neoplasm.